Bone Pain, Metastatic Bone Tumor, Bone Metastases in Subjects With Advanced Cancer
Conditions
Keywords
samarium, radioligand, radioisotope, metastatic bone pain palliation, Samarium-153, DOTMP, bone-seeking radiopharmaceutical
Brief summary
This is an open label, 2-part early phase study designed to evaluate the safety, pharmacokinetics, radiation dosimetry, and preliminary efficacy of TLX090-Tx in patients with painful bone metastases.
Interventions
DRUG153Sm-DOTMP
TLX090-Tx will be administered as a single ascending intravenous dose to participants with at least 1 confirmed painful osteoblastic bone tumor that exhibits avid uptake as shown by 99mTcdiphosphonate bone scans undertaken within 60 days of dosing.
Sponsors
Telix Pharmaceuticals (Innovations) Pty Limited
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants have had disease progression while on anti-cancer treatment, and are not eligible for the treatments, or their lesions are not amenable to palliative EBRT. * Participants must have a histologically confirmed diagnosis of malignancy at any time prior to their participation in this clinical trial with multiple metastatic bone lesions with at least 1 metastatic painful osteoblastic tumor that causes a minimum pain score of 4 on the NRS11. * Participants must have bone cancer in one or more skeletal locations as identified by a 99mTc-diphosphonate bone scan within 60 days of dosing. At least one lesion must be osteoblastic. If described as osteosclerotic, radiology confirmation that the lesion is osteoblastic is required. Adequate organ function, including: * Renal function, defined as a measured creatinine clearance (CrCl) ≥30 mL/min as per Cockroft Gault or based on radioisotope glomerular filtration rate (GFR). * Hematologic function, defined as a platelet count of \>100,000 cells/mm3 and an Absolute neutrophil count (ANC) of \>1000 cells/mm3. * Hemoglobin ≥8 g/dL. * Liver function: * Total bilirubin ≤1.5 × the upper limit of normal (ULN). * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤5 × ULN with participants with known liver metastases. * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤3 × ULN with participants with Gilbert's Syndrome. * Life expectancy of at least 16 weeks from the date of study drug administration (Day 1). * Karnofsky performance status \>60%, assessed during the screening period prior to study drug administration.
Exclusion criteria
* Participants are pregnant or breastfeeding. * Participants who have received maximum tolerable radiation to the spinal cord, have untreated pathologic bone fracture, spinal cord compression, unstable spine, or imminent long bone fracture. * Participants with a bone scan pattern showing diffuse, intense skeletal uptake with absent or faint kidney / bladder activity, typically indicating widespread bone metastases or high bone turnover from metabolic or hematologic diseases (Superscan) pattern on Technetium 99-m bone scan scintigraphy - defined as diffusely increased skeletal uptake with absent or markedly reduced renal and soft tissue visualization - are excluded from the study. * Participants with impending or suspected or at high risk for spinal cord compression. * Participants with neurogenic pain or significant pain associated with soft tissue lesions or other pain that, in the opinion of the Investigator, might interfere with the assessment of pain relief for bone tumors. * Participants who require surgery over their trial period that would require pain medication or analgesia. * Clinically significant illness or clinically relevant trauma within 2 weeks before the administration of the investigational product. * History of unstable angina (defined as angina at rest) or new-onset angina diagnosed within the 3 months prior to screening. * History of myocardial infarction within 3 months prior to screening, as determined by medical history / Baseline ECG. * Uncontrolled cardiac arrhythmias (≥Grade 3 CTCAE version 5.0) or any history of ≥Grade 3 arrhythmia. * Congestive heart failure ≥New York Heart Association Class 2. * Clinically significant abnormalities on ECG at screening including corrected QT interval (Fridericia's formula) \>450 msec for males or 470 msec for females at screening. * Inability to complete the needed investigational and standard imaging examinations due to any reason (eg, severe claustrophobia, inability to lie still for the entire imaging time). * Presence of any other condition that may increase the risk associated with study participation or interfere with the interpretation of study results, and, in the opinion of the study Investigator, would make the participant inappropriate for entry into the study. * Participants with active infections (human immunodeficiency virus, human papillomavirus. Hepatitis A, Hepatitis B, and Hepatitis C).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence and severity of treatment-emergent adverse events (TEAEs) [Safety and Tolerability] | Up to 6 weeks post-dose | Incidence and severity of hematologic and non-hematologic toxicities, graded per CTCAE v5.0, assessed through 6 weeks post-dose. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in patient-reported bone pain severity using the NRS-11 scale on the form | Baseline to 16 weeks post-dose | Change in pain score using NRS-11, assessed up to 16 weeks post-dose. |
Countries
United States
Contacts
Primary ContactSahar Khan
Backup ContactSapna Shah, MD
Outcome results
None listed